Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Predictive factors ‘raise suspicion’ for emergence of bipolar disorder

Researchers have identified seven factors that predict which patients initially diagnosed with depression will later meet the diagnostic criteria for bipolar disorder.

5 Jun 2014

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

20 May 2014

Biomarker predicts bipolarity in depressed patients

Measuring plasma levels of brain-derived neurotrophic factor in patients with a first episode of depression could help to predict who will go on to develop bipolar disorder, research suggests.

7 May 2014

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.

6 May 2014

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML") to Woodfield Pharmaceutical LLC.

25 Apr 2014

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder.

9 Apr 2014

Deutsche Forschungsgemeinschaft to establish 5 new Research Units

Topics Range from Composite Structures to Personnel Decisions to Metastatic Cancer Progression / About Eleven Million Euros in Funding for Three Years

4 Apr 2014

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration to market its Monarch eTNS System in Australia.

1 Apr 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression.

31 Mar 2014

Seroxat in combination with acupuncture produces significant effect in patients with unipolar depression

Acupuncture is more effective than oral antidepressants in improving depressive symptoms, and produces fewer side effects than tricyclic antidepressants.

28 Mar 2014

New report provides link between poor health and multiple forms of discrimination

Racial and sexual minorities, women, and obese people may face more health risks because of their disproportionate exposure to discrimination, according to a new report in the Journal of Health and Social Behavior.

26 Mar 2014

Adolescence is key developmental period for obesity and depression

Depression and obesity have long been associated, but how they relate over time is less clear. New research from a Rutgers University-Camden professor shows that adolescent females who experience one of the disorders are at a greater risk for the other as they get older.

24 Mar 2014

Illness course impacts suicide risk in bipolar and depressive disorder

Differing illness course, rather than the illness itself, is the greatest determinant of the differential risk of suicide attempts between patients with bipolar disorder and those with major depressive disorder, study findings indicate.

20 Mar 2014

Researchers examine effect of vitamin D supplementation on depression

Vitamin D deficiency has been implicated in numerous health conditions in recent years, including depressed mood and major depressive disorder.

19 Mar 2014

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology".

18 Mar 2014

Frontal lobe atrophy identified in poor sleepers

US researchers have used neuroimaging to show that war veterans with poor sleep quality have reduced frontal lobe volumes.

17 Mar 2014

Alkermes initiates pivotal clinical development program for treatment of MDD

Alkermes plc today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).

6 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

Naurex's GLYX-13 receives FDA Fast Track designation

Naurex Inc. today announced that the U.S. Food and Drug Administration has granted Fast Track designation to the investigation of GLYX-13, the company's rapid-acting antidepressant in Phase 2 clinical development, as adjunctive therapy in major depressive disorder.